The inventive food holding apparatus comprises a holding area that accommodates food and warms the food with heat radiated by a bottom surface and with warm convection air. Part of the convection air forms an air curtain having a Bernoulli effect that removes excess moisture from the external surface of the food and maintains the food in a warm, crisp condition. The apparatus conditions food to attain a biologically safe noncooking temperature and to retain its freshly cooked texture and internal moisture for more than two hours. This lets restaurants serve the food longer to its customers, allowing efficient batch cooking and significantly decreasing food waste.

Machine (1) for extracting puree, or fruit juice starting from vegetable or animal food, such as a rough extractor or a fine extractor. The machine (1) comprises essentially a cylindrical body (2) having an inlet (3) for the product to treat, an outlet (4) for a part of the product that can be used and an outlet (5) for another part of product to dispose of. The rotor (6) is wheeled to a motor (80) by a shaft (15). The product that is put in the cylindrical body (2) of the machine (1) is pushed by centrifugal force by a plurality of blades (20) of the rotor (6) to pass through a sieve (7) having holes (8) and a cylindrical or conical shape. The blades (20) of the rotor (6) comprise, in particular a first portion (21) having a first concavity and a second portion (22) having a second concavity opposite to the first.

Disclosed is a beverage extraction filter that can extract in a plurality of extraction machine types. The beverage extraction filter comprises a filter unit (40) where coffee powder is housed and a planar lid unit (41) mounted to the top section of the filter unit (40). The lid unit (41) is formed in a layer structure created by a non-permeable first sheet member (42) positioned on the filter unit side (40) and a permeable second sheet member (43) layered on top of the first sheet member (42), and a hole section (42a) through which hot water is made to pass is formed in the center of the first sheet member (42).

A device (1) for extracting an ingredient in a cartridge (9) by supplying an extraction liquid such as heated water into such cartridge, includes upstream and downstream cartridge enclosing parts (7,8) relatively movable between an open position for inserting and/or removing such cartridge and a closed position for forming an extraction chamber (11) enclosing such cartridge during extraction; and a cartridge handling arrangement including a cartridge holder (10), in particular a holder fixed to or integral with the upstream part or the downstream part, for receiving and holding such cartridge against gravity when inserted and descending under gravity between the enclosing parts in the open position prior to forming the extraction chamber (11). The handling arrangement further includes at least one cartridge positioning element (39), in particular a pair of positioning elements, that horizontally guides such cartridge (9) upon reception by the holder (10) in a cartridge extraction alignment (3,3') between the upstream and downstream parts (7,8), optionally the positioning element (s) (39) being fixed to or integral with the downstream part (8) and/or having an arched portion (39') for contacting such cartridge.

A container assembly (10) for retaining a liquid (16) during aging of the liquid (16) comprises a container (12) and an oxygenator (230). The container (12) includes a container body (14) that defines a chamber (14A) that receives and retains liquid (16). The oxygenator (230) is positioned substantially within the chamber (14A). The oxygenator (230) includes a fluid source (662), one or more diffusers (672), and a valve (670). The one or more diffusers (672) are in fluid communication with the fluid source (662). The valve (670) selectively controls the introduction of a fluid from the fluid source (662) into the liquid (16) through the one or more diffusers (672). The container assembly (10) further comprises an insert retainer assembly (338) and one or more flavor inserts (440) that are received and retained by the insert retainer assembly (338).

The present invention relates to a device to regulate the level of a liquid inside a boiler of a coffee machine, having a transparent duct connected to the boiler and designed to visibly display the level of the liquid inside the boiler, a capacitive sensor that can be positioned outside the transparent duct in determined positions and designed to generate electric signals representing the presence or absence of liquid in correspondence to the position of the sensor along the transparent duct. The sensor of the device has first measuring elements and second measuring elements, both of capacitive type; the second measuring elements are positioned at a predetermined distance from the first measuring elements, and a measuring device designed to measure the impedance between the first and second measuring elements and to generate signals indicating the presence or absence of liquid in correspondence to the position of the sensor. The invention also relates to the machine that includes this device.

Disclosed in this specification is a drip filter coffee maker that includes features to improve the taste of the brewed coffee and to enhance to ease of use. In one embodiment, an integral plate burr grinder sends coffee ground down a coffee chute that feeds the filter cone. A chute door at the end of the coffee chute prevents vapors or condensation from entering the coffee chute. In another embodiment, the eject tray that carries the filter cone may be coupled with a dampened spring biasing mechanism which moderates the eject motion. Further, a pivot float may be provided within the carafe so that the user may read the carafe fill level easily.

The present invention provides apparatus and methods for adjusting the atmosphere within a substantially sealed chamber containing respiring produce. The chamber of the present invention includes inlet means to permit ambient atmosphere to enter the chamber, and outlet means to permit chamber atmosphere to exit the chamber. Methods using apparatus of the present invention comprise: (a) monitoring the oxygen concentration within the chamber;(b) following detection that the oxygen concentration in the chamber has fallen below a predetermined amount, opening the inlet means so that the amount of oxygen in the chamber increases; and(c) removing carbon dioxide from the chamber atmosphere substantially at a predetermined rate, the predetermined rate having been selected such that the carbon dioxide concentration within the chamber atmosphere does not substantially exceed a predetermined amount. The methods may also comprise opening the inlet means for a time that is approximately proportional to the difference between the detected oxygen concentration and an oxygen setpoint.

System for application of ozone on grains made up essentially by one or more ozone mixers with particulates separator (1) for injecting air in the grains mass, one or more ozone mixers (2) for injecting air in the grains mass, a base of the device for grains treatment with ozone (3), a transport and discharge device (4), and an air cooling filter (5) that can be used individually or jointly to apply ozone on the grains mass.

A grill is provided with a removable storage basket assembly for providing a conveniently accessible receptacle or storage platform for articles such as seasonings, cooking tools, towels, or other articles. The storage basket assembly includes a frame having a basket or tray that can be mounted thereto, and a handle. The handle is configured to be received within a recess formed in a shelf of the grill for removably but stably mounting the storage basket assembly on the grill.

A bottle aerator of the type having a venturi tube having a constricted section with a narrower cross-sectional section and a fluid inlet section having a wider cross-sectional section, such that the fluid pressure is lower in the constricted section compared to the pressure in the fluid inlet section, and the fluid speed is higher in the constricted section compared to the fluid speed in the fluid inlet section, which is improved by the constricted section being constructed and arranged so that when the bottle aerator is inserted into a bottle, the constricted section is positioned inside the bottle. The air inlet is provided at or below the constricted section, which allows air from outside the bottle to mix with the fluid as it passes through the constricted section, so that the fluid is aerated while still inside the bottle.

A coffee machine comprises a frothing device, wherein an internal milk channel leading to a frothing chamber is provided into which opens a bypass air inlet for operable air supply to the frothing device. A flexible milk suction line connects the frothing device with a milk supply container. Means are provided for cleaning the frothing device and the milk suction line with rinsing water from a continuous-flow water heater of the coffee machine. A controlled valve arrangement is provided which feeds rinsing water from the continuous-flow water heater to the bypass air inlet of the frothing device. A milk suction end of the milk suction line is directly or indirectly, fluid-conductively connectable with a residual water pan of the coffee machine prior to feeding rinsing water to the bypass air inlet.

A beverage machine for preparing and dispensing a hot beverage having a pump dispensing system. Hot water passes through a water distributor to infuse material in a filter basket. A coffee tank receives the brewed beverage and maintains it at an appropriate temperature. On demand, a pump dispensing system delivers the beverage through an outlet chamber and spout into a user's cup. The user manipulates a switch to vary the rate at which the pump dispensing system dispenses the beverage.

The invention proposes a device for decaffeinating a liquid. The device includes at least one cathode electrode and at least one anode electrode which are spaced apart and which are immersed in the liquid; a power supply coupled to the at least one cathode electrode and the at least one anode electrode and configured to apply power thereto, wherein the at least one cathode electrode and the at least one anode electrode are configured to generate an electric field in the liquid upon application of the power to attract caffeine molecules in the liquid to the at least one cathode electrode; wherein the at least one cathode electrode is made of or coated with an absorbing material configured to absorb at least part of the caffeine molecules that are attracted to the at least one cathode electrode.

The present invention relates to a cooking control method performed by a cooking apparatus for a food item. The method comprises obtaining a unique identifier and cooking data for the food item, and checking for a record of the unique identifier in a memory of the cooking apparatus. If a record of the unique identifier is located in the memory, then the cooking apparatus will not cook the food item. Otherwise a cooking process based on the cooking data to cook the food item is performed. Accordingly, cooking data for a given instance of a food item can only be used once in order to activate a cooking process performed by the cooking apparatus. The present invention also features product recall as well as the ability to track food item sales via a cooking data communications system.

A system and method for displaying the actual position of one or more food items on a conveyorized oven system on a display monitor. Digital images of each food item are captured, stored and processed into positional imaging data using data transmitted from sensors adjacent to the conveyorized oven system. Characteristic data for each food item may be associated with the positional imaging data. The characteristic and positional imaging data of the food items may be stored or communicated to a display monitor for the user to view.

The invention provides a new method for preparing ultra-small polymeric-lipidic delivery nanoparticles (USDNs) that were synthesized by a nanoprecipitation method followed by a layer-by-layer nanodeposition. The USDNs particle size can be controlled between 5-25 mn and provides loading capacities of 22.12% to 72.08%. Moreover, the USDNs platform provides pH controlled drug release, within a terminal release ratio of 68% at pH 5.0 and almost no release to pH of 7.5. Furthermore, based on their small sizes (5-25 nm) and unique composition, the USDNs penetrates the skin strata efficiently, release the payload at the target site as topical or transdermal treatment of a variety of skin disorders. Additionally the USDNs system can be used to treat and diagnoses other crucial diseases (Cancer, Alzheimer, etc) can be combined with various micro-needles or needles free array technologies for special application.

The present invention includes a novel method capable of identifying a compound as an imaging agent using a DAZAX-based scaffold or derivative thereof. The present invention further includes novel imaging agents. The present invention further includes a method of modifying a DAZAX-based scaffold or derivative thereof. The present invention further includes a method for imaging a sample.

The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein.

A peptide comprising a sequence for opening a tight junction of an epithelial surface and optionally a cell penetrating sequence; and related compositions, optionally comprising further pharmaceutical agents; and related methods.

A molecule comprising a lipid, a peptide and a linker to bind the lipid to the peptide which have specific amino acid sequence to bind to Epidermal Growth Factor Receptor (EGFR) of tumor cells, and a liposomal composition which is targeted by the molecule, and method for preparing thereof is disclosed.

Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.

The disclosure provides methods and compositions for suppressing retroviruses, including novel methods for treating a retroviral infection in a human in need of such treatment, comprising delivering a functional meiosis arrest female protein 1 (MARF1) to cells containing a retroviral provirus, together with novel expression constructs comprising a coding sequence encoding a functional MARF1 operatively linked to a promoter, vectors comprising such constructs, and packaging cell lines for use in making such vectors.

The present disclosure provides antibodies, and antigen-binding fragments thereof that bind to EBOV glycoprotein. The present disclosure further provides hybridoma cell lines and methods for making and using the compositions provided herein.

This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV bispecific binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.

Specific binding members that bind the ED-A isoform of fibronectin for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, and/or for use in delivery to the neovasculature of endometriotic tissue of a molecule conjugated to the specific binding member. Specific binding members that bind tenascin-C, especially the A1, A2, A3, A4 and/or D domain tenascin-C large isoform, for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, psoriatic arthritis or psoriasis, and/or for use in delivery to the neovasculature of endometriotic, psoriatic arthritic or psoriatic tissue of a molecule conjugated to the specific binding member.

Provided is a method of potentiating immunity or preventing or treating an immune-related disease comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need thereof.

The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.

Provided is a method of decreasing blood sugar level or preventing and/or treating a hyperglycemia-related disease, including administering an anti-Ang2 antibody or an antigen-biding fragment thereof to a subject in need thereof.

This document provided methods and materials involved in treating medical conditions. For example, methods and materials for using anti-Interleukin 4, anti-Interleukin 5, and/or anti-Interleukin 13 antibodies to treat asthma in a mammal identified as having a Th2 immune response using a whole blood cell-based cytokine whole blood cell-based cytokine assay are provided.

The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)≦7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)≦1×10−4 s−1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.

Agents that specifically bind to an opioid receptor in a conformationally specific way can be used to induce a conformational change in the receptor. Such agents have therapeutic applications and can be used in X-ray crystallography studies of the receptor. Such agents can also be used to improve drug discovery via compound screening and/or structure-based drug design.

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.

Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.

Provided in some embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain. Also provided in certain embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain where the native interchain cysteine amino acids have been replaced by amino acids having no thiol moiety.

The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided.

The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

Provided herein are methods of treatment to regenerate, restore or rejuvenate a tissue. Methods include making adult somatic and germ cells pluripotent for administration to a patient. Alternatively, created pluripotent cells may be differentiated to the desired tissue type and administered to a patient to repair or enhance the target tissue.

Various aspects and embodiments of the invention are directed to high-throughput phage-engineering methods and recombinant bacteriophages with tunable host ranges for controlling phage specificity.

A recombinant vector comprises simian adenovirus 36, simian adenovirus 42.1, simian adenovirus 42.2 and/or simian adenovirus 44 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-36, -42.1, -42.2 or -44 gene(s) is also described. Methods of using the vectors and cell lines are provided.

Non-naturally occurring peptides are provided that act as a Src SH2 domain antagonist of cardiotonic steroids. Pharmaceutical compositions comprising the peptides are also provided along with vectors encoding the peptides. Methods of treating a Src-associated disease and reducing Src activity in a cell are further provided and include administering or contacting a cell with an effective amount of the peptide.